This article discusses a study being conducted on an extended family in Colombia aimed at evaluating the ability of crenezumab, a drug created by pharmaceutical company Genentech, to prevent the buildup of amyloid proteins in the brain for the purpose of preventing early-onset Alzheimer's disease...
Alzheimer's disease: early diagnosis and treatment Journal of Managed Care MedicineSicuro, Franco
Learn more about Kisunla, which is used to treat adults with mild cognitive impairment (MCI) or mild dementia stage of early symptomatic Alzheimer's disease.
"This treatment option has really shifted the Alzheimer's disease landscape for patients who are diagnosed early. That's why it's so important not to wait if you're seeing changes," Kerwin said. "We know a family history of AD is a major risk factor.[1] Nearly two...
Memantine is another symptomatic treatment for moderate-to-severe Alzheimer's disease patients. It has a small beneficial effect on cognition, activity of daily living, behaviour, and overall clinical rating. Vitamin E has antioxidant properties, and may be used in some Alzheimer's disease patients...
Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease The present invention relates to use of compounds of formula (I) as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their...
There are no approved oral disease-modifying treatments for Alzheimer's disease (AD). Objectives The objective of this study was to assess efficacy and safety of blarcamesine (ANAVEX®2-73), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) in early AD through ...
The study's results have important implications for the field of Alzheimer's research and care. Currently, 6.5 million Americans have been diagnosed with Alzheimer’s disease and this number is only growing. This study highlights the importance of addressing cognitive decline through a holistic a...
A recent 2022 study, “Projecting the Long-term Societal Values of Disease-Modifying Treatment for Alzheimer’s Disease in the United States”3, quoted as many as 10 to 14 million Americans living with MCI (Mild Cognitive Impairment) of any etiology, the very mild symptomatic stage before onset...
Alzheimer's disease is the most common cause of dementia, affecting more than 55 million people worldwide. Currently, the two main approaches for treatments to delay or slow its progression target the buildup of amyloid beta peptides—which form plaques